Diabetic Osteoporosis: A Review of Its Traditional Chinese Medicinal Use and Clinical and Preclinical Research

Abstract EN

Aim.

The incidence of diabetic osteoporosis (DOP) is increasing due to lack of effective management over the past few decades.

This review aims to summarize traditional Chinese medicine (TCM) suitability in the pathogenesis and clinical and preclinical management of DOP.

Methods.

Literature sources used were from Medline (Pubmed), CNKI (China Knowledge Resource Integrated Database), and CSTJ (China Science and Technology Journal Database) online databases.

For the consultation, keywords such as diabetic osteoporosis (DOP), TCM, clinical study, animal experiment, toxicity, and research progress were used in various combinations.

Around 100 research papers and reviews were visited.

Results.

Liver-spleen-kidney insufficiency may result in development of DOP.

18 clinical trials are identified to use TCM compound prescriptions for management of patients with DOP.

TCM herbs and their active ingredients are effective in preventing the development of DOP in streptozotocin (STZ) and alloxan as well as STZ combined with ovariectomy insulted rats.

Among them, most frequently used TCM herbs in clinical trials are Radix Astragali, Radix et Rhizoma Salviae Miltiorrhizae, Radix Rehmanniae Preparata, and Herba Epimedii.

Some of TCM herbs also exhibit toxicities in clinical and preclinical research.

Conclusions.

TCM herbs may act as the novel sources of anti-DOP drugs by improving bone and glucolipid metabolisms.

However, the pathogenesis of DOP and the material base of TCM herbs still merit further study.